Get the content you want anytime you want.

Healthcare professionals and thought leaders share their knowledge and insights on an array of infectious disease topics

Latest Videos

What Makes <em>Elizabethkingia</em> Unique?
Emil Lesho, DO, FACP, FIDSA, FSHEA, explains what makes Elizabethkingia unique.
How to Create Institution-Specific Antibiotic Stewardship Interventions
Contagion® Editorial Advisory Board member, James S. Lewis, PharmD, FIDSA, shares how antibiotic stewards can craft stewardship interventions to their own reality.
Fighting <i>Pseudomonas</i>: Impact On Patient Prognosis & Approaches to Combat Infection
Peter L. Salgo, MD; Jason Pogue, PharmD, BCPS-AQID; Andrew Shorr, MD; Marin Hristos Kollef, MD; and Yoav Golan, MD, reflect on the impact that Pseudomonas infections have on patients’ prognoses and outline the basic treatment approaches they take to combat these infections.
Long-Acting Injectable ART: Benefits & Misconceptions
Joseph Eron, MD, discusses benefits of long-acting injectable antiretroviral therapy as well as misconceptions.
MDR Infections: Overview of Antimicrobial Stewardships
Peter L. Salgo, MD; Jason Pogue, PharmD, BCPS-AQID; Debra Goff, PharmD, FCCP; and Sandy J. Estrada Lopez, PharmD, BCPS (AQID), outline the function of antimicrobial stewardships regarding multidrug-resistant bacterial infections and emphasize the importance of personnel at all levels within this system.
Nurses & Disinfection Practices: What Role Do They Play?
Barley Chironda, RPN, CIC, explains the role that nurses play in disinfection practices at health care facilities.
New Treatments on the Horizon for <i>Pseudomonas</i> Infections
Marin H. Kollef, MD, discusses new therapies in development for the treatment of Pseudomonas infections.
Gram-Positive NIs: Costs of Lipoglycopeptide Therapy
Peter L. Salgo, MD; Debra Goff, PharmD, FCCP; Andrew Shorr, MD; Sandy J. Estrada Lopez, PharmD, BCPS (AQID); and Jason Pogue, PharmD, BCPS-AQID, identify the balance that needs to be struck between cost and effectiveness in the context of lipoglycopeptide therapy for gram-positive nosocomial infections.
Big advances in treatment can